{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "L",
          "alt": "P",
          "position": "166"
        },
        "variant_string_id": "DJ-1 L166P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the DJ-1 gene are associated with recessive, early onset Parkinson’s disease (PD).",
          "judgment": "Yes",
          "reasoning": "The disease is defined as early onset Parkinson’s disease, and DJ-1 mutations are linked to it."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We have previously reported that one of the point mutations, L166P, destabilizes the protein and thus produces an effective knockout of the gene.",
          "judgment": "Yes",
          "reasoning": "The mutation is known to destabilize the protein, which aligns with the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Basic controls were not explicitly mentioned in this section.",
          "judgment": "No",
          "reasoning": "The basic controls for this assay are not clearly stated."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "This is a previously validated assay, specifically the proteasome inhibition assay.",
          "judgment": "Yes",
          "reasoning": "The assay has been previously validated in other studies."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The OddsPath calculation was not explicitly mentioned for this variant.",
          "judgment": "No",
          "reasoning": "There is no direct OddsPath calculation provided in the paper."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "However, there are multiple benign/pathogenic variants used across the study.",
          "judgment": "Yes",
          "reasoning": "The number of controls is sufficient for this step."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "OddsPath calculation is not provided, so we will infer from the statistics.",
          "judgment": "No",
          "reasoning": "No direct OddsPath value is given in the paper."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "This variant, L166P, has a supporting pathogenic strength rating due to its destabilizing effect on the protein and alignment with disease mechanism."
    }
  ]
}